Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 6/20 | 0.48 |
| ▸ | MGLL | Q99685 | 5/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515840 | 1.00 | ENPP2 (0.50) | ENPP2PTGS2FAAHMGLLEGFR | |
| Methylphenylsulfone SCHEMBL28253216 | 0.86 | PTGS2 (0.54) | PTGS2FAAHMGLLEGFRBRAF | |
| SCHEMBL7467876 | 0.82 | CA2 (0.54) | CA9 | |
| SCHEMBL7467884 | 0.82 | CA2 (0.54) | CA9 | |
| SCHEMBL12360950 | 0.79 | CA9 (0.52) | CA9 | |
| SCHEMBL14298196 | 0.79 | CA9 (0.52) | CA9 | |
| SCHEMBL8304940 | 0.79 | HTR6 (0.52) | PTGS2CA9 | |
| SCHEMBL4033649 | 0.78 | GRIN2B (0.57) | ENPP2PTGS2GSR | |
| SCHEMBL9136413 | 0.78 | ENPP2 (0.48) | ENPP2PTGS2GSR | |
| SCHEMBL8289058 | 0.78 | GRIN2B (0.57) | ENPP2PTGS2GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110642748-B | O- (2-trifluoromethyl-2-hydroxyethyl) oxime ether derivative and synthetic method and application thereof | 华南理工大学 | 2023-03-31 | — | — | CN | disclosed |
| CN-110642748-A | O- (2-trifluoromethyl-2-hydroxyethyl) oxime ether derivative and synthetic method and application thereof | 华南理工大学 | 2020-01-03 | — | — | CN | disclosed |
| US-8742117-B2 | Oxime derivatives | CADILA HEALTHCARE LIMITED (IN) | 2014-06-03 | — | — | US | disclosed |
| EP-2379542-B1 | NOVEL OXIME DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2013-02-13 | — | — | EP | disclosed |
| US-20120028996-A1 | NOVEL OXIME DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028996-A1 | NOVEL OXIME DERIVATIVES | CYP11B2, CYP11B1, PYGL | ENPP2 1353/4885PTGS2 216/4885FAAH 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.